Want to join the conversation?
Jeff Holford with Jefferies asks about the ACV franchise, the ex-US sales over the next few quarters. $BMY said it has seen the maturation of its business in Japan. New competitive entrants have significantly reduced $BMY's performance there. In Europe, the company continues to sustain a very high penetration of the genotype 3 patient population.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)